Valentin Mandin, Amandine Dupuy, Adrien Tissot, Nicolas Degauque, Richard Danger, Hoa Le Mai, Sophie Brouard
{"title":"肺移植中的细胞外囊泡:生物标志物、病理生理因素和治疗武器?","authors":"Valentin Mandin, Amandine Dupuy, Adrien Tissot, Nicolas Degauque, Richard Danger, Hoa Le Mai, Sophie Brouard","doi":"10.1002/eji.70042","DOIUrl":null,"url":null,"abstract":"<p>In the field of lung transplantation (LTx), the survival of lung transplant recipients (LTRs) is limited by events such as primary graft dysfunction (PGD), infections, and acute rejection (AR), which promote the development of chronic lung allograft dysfunction (CLAD). Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as key players in LTx because of their roles in immune regulation, inflammation, and antigen presentation. EVs carry immunologically active molecules such as MHC class I/II proteins, cytokines, and lung self-antigens (SAgs), suggesting their involvement in infections and both AR and CLAD. Recent studies indicate that EVs have diagnostic and prognostic potential. EVs expressing HLA-G and SAgs correlate with graft outcomes, while circulating EV-associated miRNAs are being evaluated as noninvasive biomarkers of rejection. In addition to their diagnostic potential, mesenchymal stem cell-derived EVs show promise in managing PGD by reducing inflammation, mitigating ischemia‒reperfusion injury, and enhancing lung repair. In conclusion, EVs contribute to pathogenesis, have potential as biomarkers, and hold promise as tools for improving LTx outcomes as therapeutic agents, yet further research is needed to validate their clinical application in the prediction and management of CLAD.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 9","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.70042","citationCount":"0","resultStr":"{\"title\":\"Extracellular Vesicles in Lung Transplantation: Biomarkers, Pathophysiological Players, and Therapeutic Weapons?\",\"authors\":\"Valentin Mandin, Amandine Dupuy, Adrien Tissot, Nicolas Degauque, Richard Danger, Hoa Le Mai, Sophie Brouard\",\"doi\":\"10.1002/eji.70042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In the field of lung transplantation (LTx), the survival of lung transplant recipients (LTRs) is limited by events such as primary graft dysfunction (PGD), infections, and acute rejection (AR), which promote the development of chronic lung allograft dysfunction (CLAD). Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as key players in LTx because of their roles in immune regulation, inflammation, and antigen presentation. EVs carry immunologically active molecules such as MHC class I/II proteins, cytokines, and lung self-antigens (SAgs), suggesting their involvement in infections and both AR and CLAD. Recent studies indicate that EVs have diagnostic and prognostic potential. EVs expressing HLA-G and SAgs correlate with graft outcomes, while circulating EV-associated miRNAs are being evaluated as noninvasive biomarkers of rejection. In addition to their diagnostic potential, mesenchymal stem cell-derived EVs show promise in managing PGD by reducing inflammation, mitigating ischemia‒reperfusion injury, and enhancing lung repair. In conclusion, EVs contribute to pathogenesis, have potential as biomarkers, and hold promise as tools for improving LTx outcomes as therapeutic agents, yet further research is needed to validate their clinical application in the prediction and management of CLAD.</p>\",\"PeriodicalId\":165,\"journal\":{\"name\":\"European Journal of Immunology\",\"volume\":\"55 9\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.70042\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/eji.70042\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eji.70042","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Extracellular Vesicles in Lung Transplantation: Biomarkers, Pathophysiological Players, and Therapeutic Weapons?
In the field of lung transplantation (LTx), the survival of lung transplant recipients (LTRs) is limited by events such as primary graft dysfunction (PGD), infections, and acute rejection (AR), which promote the development of chronic lung allograft dysfunction (CLAD). Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as key players in LTx because of their roles in immune regulation, inflammation, and antigen presentation. EVs carry immunologically active molecules such as MHC class I/II proteins, cytokines, and lung self-antigens (SAgs), suggesting their involvement in infections and both AR and CLAD. Recent studies indicate that EVs have diagnostic and prognostic potential. EVs expressing HLA-G and SAgs correlate with graft outcomes, while circulating EV-associated miRNAs are being evaluated as noninvasive biomarkers of rejection. In addition to their diagnostic potential, mesenchymal stem cell-derived EVs show promise in managing PGD by reducing inflammation, mitigating ischemia‒reperfusion injury, and enhancing lung repair. In conclusion, EVs contribute to pathogenesis, have potential as biomarkers, and hold promise as tools for improving LTx outcomes as therapeutic agents, yet further research is needed to validate their clinical application in the prediction and management of CLAD.
期刊介绍:
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.